The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis

被引:0
|
作者
Choshi, Tomokazu [1 ]
Mamoto, Kenji [1 ]
Yamada, Yutaro [1 ]
Okano, Tadashi [1 ]
Anno, Shohei [2 ]
Orita, Kazuki [2 ]
Iida, Takahiro [3 ]
Tada, Masahiro [4 ]
Inui, Kentaro [5 ]
Koike, Tatsuya [6 ]
Nakamura, Hiroaki [1 ]
机构
[1] Osaka Metropolitan Univ, Osaka, Japan
[2] Yodogawa Christians Hosp, Osaka, Japan
[3] Koryokai Hosp, Osaka, Japan
[4] Osaka City Gen Hosp, Osaka, Japan
[5] Saiseikai Nakatsu Hosp, Osaka, Japan
[6] Shirahama Fdn Hlth & Welf, Search Inst Bone & Arthrit Dis SINBAD, Shirahama, Japan
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
0426
引用
收藏
页码:826 / 827
页数:2
相关论文
共 50 条
  • [31] Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
    Zoltán Szekanecz
    Maya H. Buch
    Christina Charles-Schoeman
    James Galloway
    George A. Karpouzas
    Lars Erik Kristensen
    Steven R. Ytterberg
    Attila Hamar
    Roy Fleischmann
    Nature Reviews Rheumatology, 2024, 20 : 101 - 115
  • [32] HERPES ZOSTER INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS EXPOSED TO BIOLOGICAL AGENTS AND JAK INHIBITORS. REAL-WORLD EVIDENCE.
    Freites Nunez, D.
    Abasolo, L.
    Penuelas, M.
    Candel, F. J.
    Font, J.
    Lois, P.
    Martinez Prada, C.
    Fernandez, B.
    Madrid Garcia, A.
    Rodriguez Rodriguez, L.
    Colomer, J. I.
    Leon, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1440 - 1440
  • [33] INCREASED THROMBOEMBOLIC RISK OF JAK INHIBITORS AFTER SWITCHING FROM BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Eun, Y.
    Seo, G. H.
    Kang, S. Y.
    Lee, S.
    Kim, H.
    Cha, H. S.
    Koh, E. M.
    Lee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1337 - 1337
  • [34] Biological agents: a novel approach to the therapy of rheumatoid arthritis
    Lorenz, HM
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (07) : 1479 - 1490
  • [35] Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
    Kang, Eun Ha
    Liao, Katherine P.
    Kim, Seoyoung C.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (07)
  • [36] Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
    Eun Ha Kang
    Katherine P. Liao
    Seoyoung C. Kim
    Current Rheumatology Reports, 2018, 20
  • [37] Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
    Harigai, Masayoshi
    RHEUMATOLOGY, 2019, 58 : 34 - 42
  • [38] Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in patients with rheumatoid arthritis who discontinued JAK inhibitor therapy
    Andrea, Amstad
    Eleftherios, Papagiannoulis
    Almut, Scherer
    Andrea, Rubbert-Roth
    Axel, Finckh
    Ruediger, Mueller
    Jean, Dudler
    Burkhard, Moller
    Peter, Villiger M.
    Martin, Schulz M. P.
    Diego, Kyburz
    SWISS MEDICAL WEEKLY, 2022, 152 : 5S - 5S
  • [39] THE RELATIONSHIP BETWEEN JAK INHIBITORS AND CREATINE KINASE ELEVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-WORLD CLINICAL STUDY
    Tada, M.
    Okano, T.
    Mamoto, K.
    Yamada, Y.
    Orita, K.
    Mandai, K.
    Anno, S.
    Iida, T.
    Inui, K.
    Koike, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1321 - 1322
  • [40] Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis
    Novella-Navarro, Marta
    Plasencia, Chamaida
    Tornero, Carolina
    Navarro-Compan, Victoria
    Cabrera-Alarcon, Jose L.
    Peiteado-Lopez, Diana
    Nuno, Laura
    Monjo-Henry, Irene
    Franco-Gomez, Karen
    Villalba, Alejandro
    Balsa, Alejandro
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)